Chief Medical Review Officer, Paul Teynor, MD, to be named Chief Medical Officer of WorkforceQA After more than 28 years of providing Medical Review Officer (MRO) services, Paul Teynor, MD, Chief Medical Review Officer and Chief Medical Officer of WorkforceQA, LLC. will be reducing his involvement in day-to-day activities effective January […]
Account Transition
We have recently begun transitioning accounts to a new account management platform. While this transition will provide a higher level of service and an improved customer experience, we recognize that some may be experiencing service issues. If you are experiencing delays or issues with your service, please contact our client services […]
Q&A: DOT Expanded Testing Panel
We had great attendance and participation during our webinars on the new DOT rule concerning the expanded testing panel and what it means for employers. We have compiled all the questions we received and have provided our answers. Please click below to access the Q&A document from the webinar. Thanks […]
Watch Webinar: DOT Testing Panel Update
In case you missed it, below is a link to the webinar we hosted about the expanded DOT panel and what this new rule means for employers. For more information, please check out our other blog posts. Click Here to View Webinar Username: guest Password: webinar
Free Webinar: DOT Testing Panel – What You Need To Know
Please join us for a free webinar on the new 49 CFR Part 40 final rule that was published Nov 13, 2017, by the DOT. This rule expands DOT drug testing to include opioids, hydrocodone, hydromorphone, oxycodone, and oxymorphone and is effective January 1, 2018. Our compliance experts, Dr. Donna Smith and Sandra Vanderploeg, will be arming you with all the […]
DOT Final Rule On Expanded Opiates
The long-awaited revisions to 49 CFR Part 40 were published November 13, 2017. The final rule caps a nine months rulemaking process by the DOT and is in effect January 1, 2018. The rule primarily harmonizes DOT regulations with the revised HHS Mandatory Guidelines established by the U.S. Department of […]
DOT Expanded Opiates Drug Test TBD
The long-anticipated expansion of the drug testing panel to include the opioid drugs (i.e., hydrocodone, hydromorphone, oxycodone and oxymorphone) for DOT-mandated testing will NOT take place on October 1, 2017. The DOT will continue its rulemaking process to issue a final rule revising 49 CFR Part 40, and once complete, […]
Maintenance of Way – Drug & Alcohol Testing
The Federal Railroad Administration (FRA) is expanding its drug and alcohol testing regulations to include Maintenance of Way (MOW) employees. Effective June 12th, 2017, railroad employees and contractors who perform maintenance of way (MOW) functions for a railroad will be subject to testing under the FRA guidelines. WorkforceQA recently hosted a webinar […]
Revisions to FRA Regulations (49 CFR Part 219)
Maintenance of Way (MOW) Employees Effective June 12, 2017 In response to Congress’ mandate in the Rail Safety Improvement Act of 2008 (RSIA), the Federal Railroad Administration (FRA) is expanding the scope of its drug and alcohol regulation to cover Maintenance of Way (MOW) employees. 1. To whom does this […]
WorkforceQA Comments on DOT Drug Testing Changes
WorkforceQA recently submitted comments to the Department of Transportation (DOT) and Office of Drug and Alcohol Policy and Compliance (ODAPC) regarding proposed changes in procedures for transportation workplace drug and alcohol testing programs. In the comments WorkforceQA supported the addition of expanded opiates (hydrocodone, hydromorphone, oxymorphone, and oxycodone) in the […]